Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol RH-1-002: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic dose-escalation study of RH-1 administered as a 3-hour intravenous infusion in patients with solid tumors or non-Hodgkin's lymphoma

Next Previous
X
Search
Trial Profile

Protocol RH-1-002: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic dose-escalation study of RH-1 administered as a 3-hour intravenous infusion in patients with solid tumors or non-Hodgkin's lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RH 1 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Allos Therapeutics

    • Most Recent Events

    • 06 May 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Estimated patient numbers amended from 83 to 60 as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Status changed from active, no longer recruiting to discontinued, asreported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top